Detail akcie Cerenis Thera. online

Business Summary: Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Abionyx Pharma SA revenues decreased 10% to EUR2.1M. Net loss increased 10% to EUR2.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Discovery and development of innovative therapies segment loss increase of 10% to EUR2.3M.